Prognostic value of integrating circulating tumour cells and cell-free DNA in non-small cell lung cancer

Prognostic value of integrating circulating tumour cells and cell-free DNA in non-small cell lung cancer

Background: Non-small cell lung cancer (NSCLC) often presents at an incurable stage, and majority of patients will be considered for palliative treatment at some point in their disease. Despite recent advances, the prognosis remains poor, with a median overall survival of 12–18 months. Liquid biopsy...

Full description

Bibliographic Details
Main Authors: Joanna Kapeleris, Juliana Müller Bark, Shanon Ranjit, Darryl Irwin, Gunter Hartel, Majid Ebrahimi Warkiani, Paul Leo, Connor O'Leary, Rahul Ladwa, Kenneth O'Byrne, Brett G.M. Hughes, Chamindie Punyadeera
Format: Article
Language:English
Published: Elsevier 2022-07-01
Series:Heliyon
Subjects:
Non-small cell lung cancer
Liquid biopsy
Circulating tumour cells and clusters
Circulating tumour DNA
Cell-free DNA
Progression-free-survival
Online Access:http://www.sciencedirect.com/science/article/pii/S2405844022012592

Internet

http://www.sciencedirect.com/science/article/pii/S2405844022012592

Similar Items